Spring Seed Grant 2025 in partnership with Patients Associations – Call for Applications

The Spring Seed Grant 2025 initiative, in partneship with Patients Associations, is now open. The initiative aims to fund seed research projects through 4 single-center calls, for 12-month proposals with a maximum budget of € 50.000, focusing on the following rare genetic diseases:

  • Anderson-Fabry Disease (AFD)
  • SATB2-associated Syndrome (SATB2)
  • Sturge-Weber Syndrome (STUWE)
  • Jamuar Syndrome or UGDH-related disorder (UGDH)

For these monothematic calls, Fondazione Telethon established a collaboration agreement with the following Patients Associations:

These calls will allow the generation of data and the creation of new knowledge to pave the road for the development of new therapeutic approaches for rare genetic diseases.

Investigators - working either in public or private Italian non-profit research Institutions, including the Fondazione Telethon Institutes (SR-TIGET and TIGEM) are eligible regardless of their funding status with Fondazione Telethon ETS.

Applicants can submit only one project within the Spring Seed Grant 2025 initiative, as Lead Applicant.

All the documents related to the Spring Seed Grant 2025 calls are listed below and accessible through the links or on the Fondazione Telethon Grant Management System portal at this link.

Calls Deadlines

April 1st, 2025: calls opening

by April 15th,  2025 applicants should:

  • login or register on the Fondazione Telethon Grant Management System portal at this link
  • insert the title of the project
  • fill in the Type of Research section, providing the disease name and code, research type and research step

Filling in these data by April 15th 2025 is not mandatory.

  • May 6th, 2025, at 1 pm: project submission deadline.

Download the call texts here:

  • Anderson-Fabry Disease (AFD)
  • SATB2-associated Syndrome (SATB2)
  • Sturge-Weber Syndrome (STUWE)
  • Jamuar Syndrome or UGDH-related disorder (UGDH)

Download the other call documents here:

For further information, please contact us at [email protected]

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.